NEW BRUNSWICK, N.J., June 9 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ('Senesco' or the 'Company') (NYSE Amex: SNT) today announced the appointment, effective June 8, 2009, of its current Board member, Dr. Harlan Waksal, M.D., to serve as Chairman of the Board, succeeding Mr. Rudolf Stalder, who has been the Company's Chairman since January 2000. Mr. Stalder will continue serving on the Board and also serve as a member of a newly formed Executive Committee that includes Dr. Harlan Waksal, Mr. Christopher Forbes and Mr. Rudolf Stalder.
Dr. Waksal joined the Board of Senesco in October 2008. Dr. Waksal is President and sole Proprietor of Waksal Consulting L.L.C. in Montclair, NJ. From 1984 through July 2003, he was with ImClone Systems Inc., New York, NY, serving most recently as President, Chief Executive Officer and Chief Operating Officer.
Dr. Waksal is a member of the Board of Trustees of Oberlin College Ohio, a member of the Board of Trustees and chair of the New Jersey Region of the American Committee for the Weizmann Institute of Science in New York, and a member of the Board of Trustees of the Montclair Art Museum.
The Board is also pleased to announce, effective June 8, 2009, the appointment of Mr. Warren J. Isabelle, CFA to the Board. Mr. Isabelle is a founder and principal of Ironwood Investment Management L.L.C., located in Boston, MA. From 1983-1997, Mr. Isabelle was with Pioneer Management Corporation where he served most recently as Director of Research and Head of U.S. Equities. Mr. Isabelle also serves as a member of the Public Board and the Investment Committee of the University of Massachusetts Foundation.
Mr. Stalder commented, 'With Senesco's groundbreaking technologies, its research focus on human health and its plans to move diligently into clinical trials with a Multiple Myeloma cancer project, the recent addition of Dr. Waksal to Senesco's Board gave us a unique opportunity to ask him to take on these new responsibilities as Chairman of the Board. His experience in this area will best serve our efforts moving forward. We are very pleased about his acceptance of this significant role.'
Dr. Waksal commented about his new responsibilities, 'I am excited to take on this new role in a company that is applying cutting edge science to areas of unmet medical need.
